Italia markets close in 1 hour 38 minutes
FTSE MIB
34.238,16 +298,41 (+0,88%) Dow Jones
38.238,29 +152,49 (+0,40%) Nasdaq
15.877,91 +266,15 (+1,70%) Nikkei 225
37.934,76 +306,28 (+0,81%) Petrolio
84,04 +0,47 (+0,56%) Bitcoin EUR
60.135,49 +946,13 (+1,60%)
UCB SA (UCB.BR)
Brussels - Brussels Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
In data: 03:36PM CEST. Mercato aperto.
| Chiusura precedente | 123,75 |
| Aperto | 123,30 |
| Denaro | 0,00 x 0 |
| Lettera | 0,00 x 0 |
| Min-Max giorno | 121,85 - 124,15 |
| Intervallo di 52 settimane | 65,40 - 125,20 |
| Volume | |
| Media Volume | 307.108 |
| Capitalizzazione | 23,494B |
| Beta (5 anni mensile) | 0,40 |
| Rapporto PE (ttm) | 70,34 |
| EPS (ttm) | 1,76 |
| Prossima data utili | 24 lug 2024 - 03 ago 2024 |
| Rendimento e dividendo (futuro) | 1,36 (1,09%) |
| Data ex dividendo | 26 apr 2024 |
| Stima target 1A | 125,90 |
GlobeNewswireClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery
SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB’s gene therapy portfolio. “We are extremely excited to partner with UCB, a global biopharmaceutical leader, with a focus on inno
© 2024 Yahoo. Tutti i diritti riservati.